Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease

Nibal Ackl1, Marcus Ising, Yvonne A Schreiber

  • 1Department of Psychiatry, Memory Clinic, Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, 80802 Munich, Germany. ackl@mpipsykl.mpg.de

Insights

Mild cognitive impairment (MCI) shares hippocampal abnormalities with Alzheimer's disease (AD), suggesting MCI is a precursor stage. Neurochemical findings in the hippocampus may help stage cognitive decline.

Area of Science:

  • Neuroimaging and Neuroscience
  • Biomarkers for neurodegenerative diseases

Background:

  • Mild cognitive impairment (MCI) is a significant risk factor for Alzheimer's disease (AD).
  • Identifying reliable biomarkers for MCI is crucial for early diagnosis and intervention.
  • Understanding neurochemical changes in MCI can elucidate its relationship with AD.

Purpose of the Study:

  • To investigate shared neurochemical abnormalities between MCI and AD in early-affected brain regions.
  • To determine if neurochemical deficits in MCI correlate with neuropsychological impairments.
  • To assess the potential of proton spectroscopy as a biomarker for staging cognitive decline.

Main Methods:

  • Proton spectroscopy (1H MRS) was performed on 19 MCI patients, 18 AD patients, and 22 controls.
  • Regions of interest included parietal gray and white matter (PGM/PWM) and the hippocampus (HIP).
  • Neuropsychological testing included verbal fluency (VF) and delayed verbal recall (DVR).

Main Results:

  • Reduced N-acetyl-aspartate to creatine ratio (NAA/Cr) was observed in the hippocampus for both MCI and AD patients compared to controls.
  • AD patients, but not MCI patients, exhibited parietal lobe neurochemical abnormalities (e.g., elevated myoinositol).
  • MCI patients showed significant deficits in VF and DVR, which correlated with hippocampal NAA/Cr and parietal myoinositol levels.

Conclusions:

  • Shared hippocampal neurochemical abnormalities in MCI and AD provide biological evidence for MCI as an AD precursor.
  • Parietal lobe neurochemistry remains normal in MCI, differentiating it from AD.
  • Multivoxel 1H MRS shows promise for objectively staging neurodegeneration in age-dependent cognitive deficits.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Role of Hippocampus in Memory01:19

Role of Hippocampus in Memory

The hippocampus, a critical brain structure, plays an essential role in memory processing, particularly in the formation and retrieval of memory. This small, seahorse-shaped region is located within the medial temporal lobe, with one hippocampus in each brain hemisphere. Experimental studies involving lesions in the hippocampi of rats have demonstrated significant impairments in tasks such as object recognition and maze navigation, indicating the hippocampus involvement in both recognition and...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...